Mylan says US FDA's generic user fee not discriminatory despite foreign inspection cost differential
This article was originally published in SRA
Executive Summary
US generic manufacturer Mylan believes that any claims of bias against foreign manufacturers within the US Food and Drug Administration's proposed generic drug user fee plan are "misplaced" and that the programme offers parity for all industry participants1. The US firm, seen as a "driving force" behind the proposal, also sees the programme securing American competitiveness and jobs.